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PV tree was developed where pressure was modeled as the product of chain- 
bar elastanca and volume. An analytical solution of the unsteady Bernoulli 
equation was achieved by lineadzing the equation. The solution equation 
consisted of a cosine function, which captures visa largo, and a sine function, 
which captures vis a fmnte. Time-varying systolic PV velocity, ut(t) -cms, is 
a function of the following variables: total atrial suction created by atrial re- 
laxation (z~Paf -- mmHg) and mitral annular descent (&Pm¢ - mmHg), atrial 
(Ea - mmH~rco) and PV alastance (Epv), net atrial-- PV elactance (Enet = Ea 
+ Ew), the average rate of PV tree replenishment from the capillaries (QL -- 
cm31s), total PV cross*sectional rea at the atrial junction (A-  cm2), and PV 
inertanca (pLea -- g/cm2). This model found that tl'e peak velocity and inte- 
gral of systolic PV flow increased as atrial suction and PV tree replenishment 
increased, but decreased as atrial and PV elastanca, PV inedanca, and PV 
crsss-sectional area increased. Also, this model predicts aspects of systolic 
PV flow that are consistent with expedmental and clinical observations: (i) 
the vis a tergo component of systolic PV flow is minimized by compliant PVs 
(small PV elastanca); (if) atrial events, so-called visa fronte, dominate the 
magnitude of systolic PV flow; (iii) systolic PV flow is reduced by elevations in 
atrial pressure but onlywhan compliance is also reduced; (iv) compensatory 
increases in atrial suction and PV tree replenishment may overcome reduc- 
tions in systolic PV flow due to elevated atdal pressures; (v) PV inertanca nd 
area are important dP.terminants of the magnitude and timing of PV flow. 
U( t )=~ 1-cos  (t) + ~ sin (t) 
11:15 
~ Differential Sympathetic of  Muscle Neural Control  
Oxygenat ion in Resting and Exercising Human 
Skeletal Muscle 
Jim Hansen, Gall D. Thomas, William J. Parsons, Ronald G. Victor. UT 
Southwestern, Dallas, Texas 
Although the muscle metaboreflex triggers increases in muscle sympathetic 
nerve activity (SNA) targeted to beth resting and exercising human skeletal 
muscle, our recent rat studies advance the hypothesis that the vasocon- 
striction normally evoked by increased muscle SNA is salectively attenuated 
in the contracting muscle, thereby optimizing muscle perfusion. The abil- 
ity to continuously measure muscle oxygenation (cytochrome a,a3 redox 
state and tissue oxygen stores (t(HbO~ + MbO~)) in exercising muscle with 
near infrared spectroscopy while simultaneously measudng muscle SNA 
(micronecrography) provided a new opportunity tO test this hypothesis in 
humans. Specitically, we asked if a reflex increaSe in muscle SNA decreases 
muscle oxygenation i  resting, but not in exercising muscle. In 10 healthy hu- 
mans, we measured oxygenation in forearm muscle during reflex increases 
in muscle SNA evoked by non-hypotenslve tower body negative pressure 
(LBNP, -20 mmHg) at rest and dudng mild rhythmic handgdp (5 rain 20% of 
maximum). At re~', LBNP increased muscle SNA by 292 4. 72% (mean -*- SE) 
and decreased t(HbO2 + MbO2) by 10 4. 1% (p < 0.05) of the maximal de- 
crease (assessed with complete forearm ischemia). This decrease in t(HbO 
2 + MbO2) in the resting forearm was sympathetically-mediated because 
it was abolished by local sympathetic block with bretylium. Handgdp alone 
caused no change in muscle SNA, but rapidly decreased t(HbO2 + MbO2) 
to a steady state 28 4- 4% below baseline. Importantly, when superimposed 
on handgdp, LBNP increased MSNA by 305 4. 59%, but now had no effect 
on tissue oxygenation in the exercising muscle (zit(HbO.a ÷ MbO2) = +0.4 
4- 3%, p = ns). These data provide direct evidence in humans that reflex 
sympathetic activation decreases oxygenation in resting, but not in exercis- 
ing human skeletal muscle. This mechanism would optimize oxygenation of 
active muscle when the muscle metaboreflex iS engaged. 
11:30 
~ T h e  Pharmace-Genctice of  Congenital  Cardiac 
Defects in Retinoic Acid Receptor Oeflelent Mouse 
Embryos 
Henry M. Sucov, Vicky LaMorte, Jiangming Luo, Vincent Giguere, Ronald 
M. Evans. Univ. of Southern California SchooI of Medicine, Los Angeles, CA 
Germline mutations in several of the genes which encode receptors for the 
signaling molecule retinoic acid (PA) have been previously established in 
mica. Cardiac phenotypes which emerge in mutant embryos include defects 
in the ventricular chamber, conus, truncos, and aortic arch artedes. Based 
on new experimental and theoretical observations, the following conclusions 
have been drawn concerning the pharmacology of RA receptor function in 
mediating complex aspects of cardiac morphogenasis: (1) the level of func- 
tional receptor, known to be a heterodimsr of RAR and RXR monomers, is 
dictated by equilibrium considerations; (2) in the tissue involved in septation 
of the tmncus, the levels of RAR and RXR monomers are roughly compa- 
r'abte, explaining the emergence of persistent truncus artedosus only after 
combined mutation of PAR and RXR; (3) target genes of RA action critical in 
the morphogansSiS of the ventricular chamber contain receptor binding sites 
in their promoters of moderate, rather than high, affinity; this is also likely 
to be true in most other cases of RA action; (4) differentiation of the conus 
cushions is a significantly different response to RA than is morphoganesis of 
either the truncus or the vantricutar chamber, in that the conus is sensitive to 
beth insufficient or excess RA, whereas the tmncus and ventdcular chamber 
are sensitive to only RA deficiency; (5) the pharmacology of the RA recep- 
tors may in some cases make it possible to reverse the consequences of 
receptor mutation by treatment with exogenous RA; this approach was not 
successful in rescuing the hypoplastic ventricular phenotype, indicating that 
receptor mutation also supresses the inducible RA response to below the re- 
quired threshold in this tissue. These conclusions make testable predictions 
concerning the molecular mechanisms of normal and pathological cardiac 
morphoganesis, which will be evaluated through future molecular analysis. 
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I -4-~- '~ Localization of  the Gene for  Familial Id iopathic 
Dilated Card iomyopathy to Chromosome lq32  
Jean-Bernard Durand, Linda L. Bechinsld, Lisa Bailing, Grazyna 
Z. Czemuszewicz, Antoine B. Abchee, Qun Tec Yu, Rite Hill, Jonah Ifegwu, 
A.J. Marian, Ramon Brugada, Staven Daiger, Jane M. Gregoritch, 
Jeff Anderson, Miguel Quifiones, Jeffrey A. Towbin, Robert Roberts. Baylcr 
College of MedicirTe, I~ousten, Texas 
Cardiac failure is the tastast growing cardiovascular condition in the Western 
wodd with over 400,000 new cases per year in the U.S. The cost in the U.S. 
for cardiac transplantation alone is over $200 million and for all cardiac failure 
over $10 billion. Dilated cardiomyopathy (DCM), the most common cause 
of heart failure, is a pdmary cardiac disease charactedzed by vantricular di- 
latation and impaired systolic contraction and manifested clinically by either 
sudden death or pump failure. The cause for DCM is unknown (idiopathic, 
IDCM) with 20% estimated to be inherited. To identify the genetic defect for 
IDCM one must first map the chromosomal ocus. Thus, we studied a four 
generation kindred with ten members having IDCM, detected by echecardiog- 
raphy. IDCM segregated as a highly panetrant autosomal dominant disorder. 
A genome search was performed using short tandem repeat pofymorphic 
(STRP) markers. Two-point and multi-point linkage analysis was conducted 
assuming ponetranca to be 00%. Approximately 90% of the genome was ex- 
cluded by multi.point analysis of > 400 mad~ers. Peak led score of 5.78 was 
obtained at the marker DIS414 with t) = 0% recombination. Peak multi-point 
Iod score, also at D1S414, was 6.37. Haplotype analysis identified recombi- 
nation events between the disease gane and polymoq0hic markers in seven 
individuals. The region of lq common to all ten affected individuals is flanked 
by markers D1S249 and D1 $549 which are approximately 20 cM apart. Rea- 
sonable candidates including myosin-binding protein-H, MEF-2D, renin and 
plasma membrane calcium transporting ATPase, are known to be localized 
to this region and studies are now underway using the positional candidate 
approach to isolate and identify the responsible gane. Identification of the ge- 
netic defect should elucidate the molecular basis for familial DCM, providing 
a means for precise diagnosis and screening of asymptomaflc individuals at 
risk pdor to the development of this disease, which is a necessary step in our 
ultimate goal of providing effective prevention and treatment of this disease. 
2:15 
~ A  Functional Role fo r  Endothelin-1 in 
Norepinephrine- lnduced Ventricular Hypert rophy in 
Vivo and in Vitro 
Samer Kaddoura. MRCP, National Heart & Lung Institute, London, United 
Kingdom 
Background Endothelin-1 (ET-1) has potent effects upon call growth. We 
tested the hypothesis that endogenous ET-I plays a functional role in nore- 
pinaphfine (NE)-induced ventdcular hypertrophy by studying physical indices 
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and molecular markers of hyperlmpby, vantdcular and non-cardiac expres- 
sion of ET-1 mRNA and the effects of bessntan, an orally-active compatJlJve 
ETA and ETB receptor antagonist without adrenocoptor antagonism. Methods 
andResults Initially, a rat model of ventdcular hypertrophy due to continuous 
infusion of NE (600 #g/kg/h up to 7 days) by subcutaneous osmotic pumps 
was used. Male Sprague-Dawlay rats (175-200 g, n = 70) were divided into 4 
groups: 1. Sham.operated, 2. NE-infused, 3. Sham-opsrated given besentan 
(100 mg/kg/day by gavaga), 4. NE-infused given besantan. NE caused a 35- 
fold increase in ventdcular ET-I mRNA within 1 day (sham - ET-I:GAPDH 
mRNA, 0.01 ~- 0.01 at 1 day, n = 6 vs NE-  ET-I:GAPDH mRNA, 0.35 :E 
0.08, n = 8, P < 0.01), an effect not seen in lung, kidney or skeletal muscle. 
NE also caused significant increases in ventticular weight, RNA:protein, and 
expression of mRNAs for atrial natrluretio factor (ANF), beta-myosin heavy 
chain and skeletal alpha-aatin, which in adult ventricle are indicators of hy- 
pertrophy (fig. A). Bosentan blocked NE-induced hypertrophy at 5 days. In 
vitro, NE increased expression of ET-1 mRNA by cultured ventdcular my- 
ocytas and led to hypertrophy with increased ceU size, saroomedzation and 
expression of ANF mRNA, Myocyto protein content and [3H]-phenylalanine 
incorporation also increased, effects blocked by 10 #M bosantan (fig. B). 
Conclusion ET-1 plays a direct role in mediating NE-inducod hypertrophy 
wi~ 'Cross-talk' between these systems in vivoand in vitro. 
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~ Cis/Trans Regulation of Vascular Endothelial 
Growth Factor mRNA Stability by Hypoxia 
Andrew P. Levy, Nlna S. Levy, Mark A. Goldbarg. Boston University School 
of Medicine, Boston, MA 
Hypoxia has been shown to be an important stimulus for the formation of new 
blood vessels in the coronary collateral circulation in coronary artery disease. 
Vascular endothelial growth factor, a potent angiegsnie factor, is regulated by 
hypoxia in vitro and in viv,~. The major control point for the hypoxic induction of 
the VEGFgane is the regulat;,'~n ofthe steady-state l vel of the mRNA which is 
determined by the relative rates of mRNA synthesis and decay. We previously 
demonstrated a discrepancy between the transcription rate and the steedy- 
state mRNA level induced by hypoxia. This lead us to examine the post- 
transcdptional regulation of VEGF expression. A~nomyctn D experiments 
revealed that hypoxia increased VEGF mRNA halHife from 43 ~ 6 minutes 
to 106 ± 9 minutes. Using an in vitro mRNA degradation assay the half-life 
of VEGF mRNA 3' untranslated region (UTR) transsdpts were also found 
to be increased when incubated with hypoxic versus normoxie extracts. 
Both cis.reguiatory elements involved in VEGF mRNA degradation under 
normoxlo conditions and in increased stabilization under hypoxio conditions 
were mapped using this degradation assay. Hypsxia.induced proteins were 
identified by RNA alactremobility shift assay that bound to the sequences 
in the VEGF 3' UTR which mediated increased stability in the degradation 
assay. The binding site of one of these proteins was localized in the VEGF 3' 
UTR within 20 bases of the nonamerio sequent'e, UUAUUUAUU, previously 
shown to mediate the rapid degradation of multiple cytokine and oncogene 
mRNAs. This suggests a novel mechanism whereby these hypoxia-inducible 
proteins tabiliZe VEGF mRNA by interfering with the nonamedc site binding 
to its cognate binding protein(s). Furthermore, ganistsln, a tyrosine kinase 
inhibitor which was recently shown to inhibit he hypoxic induction of VEGF 
mRNA through its action on sre, blocked the hypoxia-induced stebilization 
of VEGF 3' UTR transcripts and inhibited hypoxia-induced protein binding to 
the VEGF 3' UTR while having no effect on the hypoxla-inducad increase 
in transcription of the VEGF gane. This suggests a signal cascade throUgh 
srrJraf and MAP kinase that has as its terminal event a protein that binds 
to VEGF mRNA and mediates its hypoxic stsbllization. An understanding of 
the molecular basis of the regulation of VEGF by hypoxia forms the essential 
groundwork for the rational design of pharmacological gents to increase 
VEGF expression and thereby augment neovsscularization i regions of 
ischemio myo(~u'dlum. 
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~ A  Novel Atherogenle Activity of  Upoprotein(a): 
Induction of Monooyte Chemotactle Activity in 
Human Umbilical Vein Endothelial Cells 
Michael Pann, Xiaoxia Zhang, Mark B. Taubman, Peter C. Haq~el. Mount 
Sinai School of Medicine, New York, IVY 
Elevated levels of lipoprotein(a) (Lp(a)) are associated with increased dsk 
of cardiovascular mortality and molt:)idity. Recruitment of monocytes to the 
blood vessal wall is an early event in the pethogenasis of atherosclerosis. 
We now report that Lp{a) induces the secretion of monocyte chemataCtic 
activity (MCA) by human umbilical vein endothelial cells (HUVEC). MCA was 
assayed using a modified Boyden Chamber. Minimal MCA was produced 
by HUVEC incubated in ssrum-free medium. Lp(a) induced MCA in HUVEC 
beginning at 30 rain and peaking at 2-3 hr. Peak levels were ~:80% of those 
seen with fomat-leu-phe, a potent monocyte chemoattractar¢ The induction 
of MCA was concentration dependent, with maximum MCA seen at 100 
p.g/ml of Lp(a). LDL from the same donor failed to induce MCA. In addCdon, 
Lp(a) had no direct chemotactic activity for monocytas. Polymyxin B failed to 
inhibit he stimulatory effect of Lp(a), suggesting that lipopolysaccharide was 
not the asth'e agent. Checkerboa¢l analysis documented that the activity 
presents in Lp{a)-cund~oned medium was pdmadly chemataclic rather than 
chemoldnetic. ConcOmitant Vaelment of HUVEC with Lp{a) and either 10 
p.M actinomycin D or cydoheximide completely inhibited the secretion of 
MCA into the culture medium, indicating that protein and RNA synthesis 
were required. It has been previously shown that oxidized LDL induces 
monocyte chemotanti¢ protein-1 (MCP-1) mRNA and activity in human aortic 
endothelial cells. In the currant study, Northem blot analysis showed that 
Lp(a) did not induce MCP-1 mRNA in HUVEC, indicating that Lp(a) may 
induce a chemoatlractant other than MCP-1. These studies suggest that 
Lp(a) may be involved in the recruibnent of monocytas to the vessel wall and 
provide a novel mechanism for the participation of Lp(a) in the atheroganic 
process. 
3:00 
~ Genetic Expression of Endothelial and Inducible 
Forms of Nitric Oxide Synthase in the Normal and 
Failing Human Hearts 
ChiMing Wei, Sh|-Wen Jiang, Richard C. Da]y, Christopher G. 
A. McGregor. Mayz) Clinic, Rochester, MN 
Niffic oxide (NO) is a potent endothelium-dedved relaxing factor which also 
may modulate cardiomyocyts inotropism and growth via increasing the cGMP 
level. While both the endothelial nitric oxide synthase (eNOS) and inducible 
nitric oxide synthase (iNOS) Isoforms have been detected in non-human 
mammalian tissues, expression and localization of the eNOS and iNOS in 
the normal and falling human heart am poorly defined. The present study 
was designed to investigate the eNOS and iNOS in human cardiac tissues 
in the presence and absence of congestive heart failure (CHF). Normal and 
falling atrial tissue were obtained from twelve cardiac donom and twelve end- 
stage heart failure patients undergoing cardiac b-ansplantation, eNOS and 
iNOS ~ion  and localization were inveslJgated utilizing Northern blot 
analysis, in situ hybridization and immunohiatochemisby. Norihem blot anal- 
ysis and in situ hybridization demonstrated similar levels of the eNOS and 
iNOS mRNA am present in cardiomyocytes from normal and falling hearts. 
Positive immunohistochemical staining was observed within the cytoplasm of 
cardiomyocytas. No significant different eNOS and iNOS immunore~es  
between normal and falling human myocardium were detected. The present 
studies demonstrated for the first time the genetic expression and d~tzi- 
bUtion of eNOS and iNOS in the normal and falling human hearts. These 
studies suggest that the NOS mediated paracdne and autocdne pa~way 
may sontinue to control the myocardial funstion in the failing human healts. 
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